Atomera Among 3 Promising Penny Stocks

As February begins, major U.S. stock indexes have shown a robust start with the Dow Jones Industrial Average gaining 515 points and the S&P 500 nearing record highs. In such a buoyant market environment, investors often seek opportunities beyond well-known large-cap stocks, turning their attention to smaller or newer companies that can offer unique growth potential. Despite its vintage connotation, the term "penny stocks" still holds relevance for those exploring affordable investment options with promising financial foundations. This article will explore three penny stocks that stand out for their financial strength and potential long-term value in today's market landscape.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating Dingdong (Cayman) (DDL) $2.89 $619.34M ★★★★★★ Waterdrop (WDH) $1.77 $640.14M ★★★★★☆ LexinFintech Holdings (LX) $2.76 $464.41M ★★★★★★ Global Self Storage (SELF) $4.99 $56.58M ★★★★★☆ Information Services Group (III) $3.11 $226.97M ★★★★★★ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Cricut (CRCT) $4.69 $993.08M ★★★★★★ Nephros (NEPH) $4.10 $43.57M ★★★★★★ Lifetime Brands (LCUT) $3.42 $77.48M ★★★★★☆ Marine Petroleum Trust (MARP.S) $4.38 $8.76M ★★★★★☆

Click here to see the full list of 345 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Atomera

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Atomera Incorporated develops, commercializes, and licenses proprietary processes and technologies for the semiconductor industry in North America and Europe, with a market cap of $126.83 million.

Operations: The company generates revenue from its Semiconductor Equipment and Services segment, totaling $0.07 million.

Market Cap: $126.83M

Atomera, with a market cap of US$126.83 million, is pre-revenue, generating only US$0.07 million in sales and experiencing a net loss of US$20.17 million for 2025. Despite its seasoned management and board, the company remains unprofitable with increasing losses over five years at an annual rate of 6.1%. Atomera's share price has been highly volatile recently, though it benefits from having no debt and sufficient cash runway for over a year based on current free cash flow trends. Recent bylaw changes align with Delaware law updates but do not materially affect disclosures.

Unlock comprehensive insights into our analysis of Atomera stock in this financial health report. Examine Atomera's past performance report to understand how it has performed in prior years.ATOM Financial Position Analysis as at Feb 2026

CBAK Energy Technology

Simply Wall St Financial Health Rating: ★★★★☆☆

Story Continues

Overview: CBAK Energy Technology, Inc. is involved in the manufacturing, commercialization, and distribution of standard and customized lithium and sodium batteries across Mainland China, Europe, and internationally with a market cap of $85.19 million.

Operations: The company's revenue is primarily derived from its CBAT segment, which accounts for $97.85 million, and the Hitrans segment, contributing $63.91 million.

Market Cap: $85.19M

CBAK Energy Technology, with a market cap of US$85.19 million, is involved in lithium and sodium battery production but remains unprofitable, with losses increasing 29.5% annually over the past five years. The company's debt management shows improvement, reducing its debt to equity ratio from 196.5% to 29.3%, and its operating cash flow covers 81.7% of its debt obligations well. Despite trading at good value compared to peers and industry standards, CBAK faces challenges as short-term assets (US$157.7 million) do not cover short-term liabilities (US$228 million), although they exceed long-term liabilities (US$17.4 million).

Jump into the full analysis health report here for a deeper understanding of CBAK Energy Technology. Evaluate CBAK Energy Technology's prospects by accessing our earnings growth report.CBAT Debt to Equity History and Analysis as at Feb 2026

Allogene Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases, with a market cap of approximately $404.51 million.

Operations: Allogene Therapeutics, Inc. does not report any revenue segments as it is currently in the clinical stage of developing its therapies.

Market Cap: $404.51M

Allogene Therapeutics, Inc., with a market cap of US$404.51 million, is pre-revenue and unprofitable, yet it holds potential in the biotech sector due to its innovative allogeneic CAR T platform. The company anticipates 2026 as a pivotal year with significant clinical readouts that could validate its off-the-shelf CAR T therapies for cancer and autoimmune diseases. Despite high volatility and recent insider selling, Allogene's financial position remains stable with short-term assets exceeding liabilities by a substantial margin. Additionally, the company is debt-free and has an experienced board overseeing its strategic direction.

Click here to discover the nuances of Allogene Therapeutics with our detailed analytical financial health report. Understand Allogene Therapeutics' earnings outlook by examining our growth report.ALLO Debt to Equity History and Analysis as at Feb 2026

Make It Happen

Dive into all 345 of the US Penny Stocks we have identified here. Looking For Alternative Opportunities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ATOMCBAT and ALLO.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments